First Time Loading...

Innovent Biologics Inc
HKEX:1801

Watchlist Manager
Innovent Biologics Inc Logo
Innovent Biologics Inc
HKEX:1801
Watchlist
Price: 40.65 HKD -2.87%
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Innovent Biologics Inc

Wall Street analysts forecast Innovent Biologics Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Innovent Biologics Inc is 56.12 HKD with a low forecast of 32.42 HKD and a high forecast of 80.85 HKD.

Lowest Forecast
Wall Street Target
32.42 HKD
20% Downside
Average Forecast
Wall Street Target
56.12 HKD
38% Upside
Highest Forecast
Wall Street Target
80.85 HKD
99% Upside
Lowest
Price Target
32.42 HKD
20% Downside
Average
Price Target
56.12 HKD
38% Upside
Highest
Price Target
80.85 HKD
99% Upside
Innovent Biologics Inc Competitors:
Price Targets
002007
Hualan Biological Engineering Inc
35% Upside
DNLI
Denali Therapeutics Inc
150% Upside
AMGN
Amgen Inc
12% Upside
302440
SK Bioscience Co Ltd
4% Downside
002007
Hualan Biological Engineering Inc
35% Upside
DNLI
Denali Therapeutics Inc
150% Upside
AMGN
Amgen Inc
12% Upside
302440
SK Bioscience Co Ltd
4% Downside
G
144510
GC Cell Corp
93% Upside
GILD
Gilead Sciences Inc
29% Upside
PYC
PYC Therapeutics Ltd
240% Upside
GRTS
Gritstone bio Inc
494% Upside

Revenue
Forecast

Revenue Estimate
Innovent Biologics Inc

For the last 6 years the compound annual growth rate for Innovent Biologics Inc's revenue is 164%. The projected CAGR for the next 3 years is 28%.

164%
Past Growth
28%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Innovent Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
12%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Innovent Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
25%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Innovent Biologics Inc's stock price target?
Price Target
56.12 HKD

According to Wall Street analysts, the average 1-year price target for Innovent Biologics Inc is 56.12 HKD with a low forecast of 32.42 HKD and a high forecast of 80.85 HKD.

What is Innovent Biologics Inc's Revenue forecast?
Projected CAGR
28%

For the last 6 years the compound annual growth rate for Innovent Biologics Inc's revenue is 164%. The projected CAGR for the next 3 years is 28%.

ALPHA SPREAD
Join more than 133,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.